Biomarkers of Oxidative Stress in Systemic Lupus Erythematosus Patients with Active Nephritis.
Lu LiuKarina de LeeuwSuzanne ArendsBerber Doornbos-van der MeerMarian L C BulthuisHarry Van GoorJohanna Westranull nullPublished in: Antioxidants (Basel, Switzerland) (2023)
Oxidative stress plays an important role in systemic lupus erythematosus (SLE) and especially in lupus nephritis (LN). The aim of this study was to compare redox-related biomarkers between patients with active LN, quiescent SLE (Q-SLE) and healthy controls (HC) and to explore their association with clinical characteristics such as disease activity in patients. We investigated levels of plasma free thiols (R-SH, sulfhydryl groups), levels of soluble receptor for advanced glycation end products (sRAGE) and levels of malondialdehyde (MDA) in SLE patients with active LN ( n = 23), patients with quiescent SLE ( n = 47) and HC ( n = 23). Data of LN patients who previously participated in Dutch lupus nephritis studies and longitudinal samples up to 36 months were analyzed. Thiol levels were lower in active LN at baseline and Q-SLE patients compared to HC. In generalized estimating equation (GEE) modelling, free thiol levels were negatively correlated with the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) over time ( p < 0.001). sRAGE and MDA were positively correlated with the SLEDAI over time ( p = 0.035 and p = 0.016, respectively). These results indicate that oxidative stress levels in LN patients are increased compared to HC and associated with SLE disease activity. Therefore, interventional therapy to restore redox homeostasis may be useful as an adjunctive therapy in the treatment of oxidative damage in SLE.
Keyphrases
- big data
- systemic lupus erythematosus
- disease activity
- rheumatoid arthritis
- machine learning
- rheumatoid arthritis patients
- ankylosing spondylitis
- oxidative stress
- juvenile idiopathic arthritis
- end stage renal disease
- newly diagnosed
- ejection fraction
- dna damage
- stem cells
- peritoneal dialysis
- ischemia reperfusion injury
- mesenchymal stem cells
- breast cancer cells
- replacement therapy
- signaling pathway
- patient reported outcomes
- cell death
- diabetic rats